NCT07479732 2026-03-18
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Peking University People's Hospital
Phase 1/2 Recruiting
Clinical Trials
113 trialsNCT07474103 2026-03-16
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Recruiting
NCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
NCT04233866 2026-03-02
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05382559 2026-03-02
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06998940 2026-02-20
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06835387 2026-02-17
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
NCT04901702 2026-02-09
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT07397819 2026-02-09
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06958328 2026-02-02
LAP100
NRG Oncology
Phase 3 Recruiting
NCT04005339 2026-01-26
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
Phase 2 Active not recruiting
NCT07281157 2025-12-30
Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06540326 2025-12-22
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT04390399 2025-12-15
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT06625320 2025-12-12
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06258642 2025-08-20
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Fudan University
Phase NA Recruiting
NCT06023641 2025-08-19
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT05385861 2025-08-15
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
National Health Research Institutes, Taiwan
Phase 1/2 Enrolling by invitation
NCT07123441 2025-08-14
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07104604 2025-08-08
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
Affiliated Cancer Hospital of Shantou University Medical College
Phase 1 Recruiting
NCT07085273 2025-07-31
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT07060014 2025-07-11
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
The Methodist Hospital Research Institute
Phase 1 Not yet recruiting
NCT03693677 2025-07-01
FUNGEMAX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT05277766 2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1 Recruiting
NCT07028424 2025-07-01
PANORAMIX
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT05854498 2025-06-12
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT07004712 2025-06-08
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06827717 2025-05-31
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06438822 2025-05-07
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
West China Hospital
Phase 2 Recruiting
NCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed
NCT03861702 2025-04-18
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03468335 2025-04-17
PREDICT
AIO-Studien-gGmbH
Phase 3 Completed
NCT06894797 2025-03-25
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT06210971 2025-03-13
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT02631733 2025-02-10
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT03736720 2025-01-30
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Phase 2 Terminated
NCT06643793 2025-01-28
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06782685 2025-01-20
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06657690 2025-01-10
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Sun Yat-sen University
Phase 2 Recruiting
NCT06766019 2025-01-09
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Active not recruiting
NCT03719924 2025-01-08
OESIRI
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT03837977 2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2 Completed
NCT06749691 2024-12-27
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06739928 2024-12-18
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Recruiting